4G8 Stock Overview
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Guerbet SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €32.45 |
| 52 Week High | €35.15 |
| 52 Week Low | €15.76 |
| Beta | 0.75 |
| 1 Month Change | 2.69% |
| 3 Month Change | 67.96% |
| 1 Year Change | 97.62% |
| 3 Year Change | -3.42% |
| 5 Year Change | -40.24% |
| Change since IPO | 1.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4G8 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.5% | -5.1% | -1.5% |
| 1Y | 97.6% | -9.0% | 0.9% |
Return vs Industry: 4G8 exceeded the German Medical Equipment industry which returned -6.2% over the past year.
Return vs Market: 4G8 exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| 4G8 volatility | |
|---|---|
| 4G8 Average Weekly Movement | 7.8% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4G8's share price has been volatile over the past 3 months.
Volatility Over Time: 4G8's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 2,839 | David Hale | www.guerbet.com |
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services.
Guerbet SA Fundamentals Summary
| 4G8 fundamental statistics | |
|---|---|
| Market cap | €417.17m |
| Earnings (TTM) | €23.87m |
| Revenue (TTM) | €796.21m |
17.5x
P/E Ratio0.5x
P/S RatioIs 4G8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4G8 income statement (TTM) | |
|---|---|
| Revenue | €796.21m |
| Cost of Revenue | €179.70m |
| Gross Profit | €616.51m |
| Other Expenses | €592.64m |
| Earnings | €23.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 25, 2024
| Earnings per share (EPS) | 1.89 |
| Gross Margin | 77.43% |
| Net Profit Margin | 3.00% |
| Debt/Equity Ratio | 0% |
How did 4G8 perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield-15%
Payout RatioDoes 4G8 pay a reliable dividends?
See 4G8 dividend history and benchmarks| Guerbet dividend dates | |
|---|---|
| Ex Dividend Date | Jul 01 2024 |
| Dividend Pay Date | Jul 03 2024 |
| Days until Ex dividend | 73 days |
| Days until Dividend pay date | 75 days |
Does 4G8 pay a reliable dividends?
See 4G8 dividend history and benchmarks